Our patent titled 8-hydroxy-quinoline derivatives protects 8-hydroxyquinolines as new racemic compounds and their therapeutic applications (priority date: May 2011; patent application number: WO2011148208 A1). This patent was granted in U.S.A., Eurasia, Australia, China, Indonesia, Japan, South-Korea, Mexico, and New-Zealand. The patent is under granting process in Europe, Canada, Brazil, and India.
Summary: The compounds of the general formula and their pharmaceutically acceptable salts can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress, which are selected from the following: ischemia, reperfusion injury, cardiovascular disorders, neurodegenerative disorders (including especially Alzheimer’s disease and Huntington’s disease), trauma, neuropsychiatric diseases (including especially depression and anxiety disorders), and liver, kidney and lung injuries.